Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Mirum Pharmaceuticals (NASDAQ: MIRM) recently:

• 7/2/2026 – Mirum Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $115.00 to $125.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Mirum Pharmaceuticals was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 6/15/2026 – Mirum Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 6/15/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Citigroup Inc..
• 6/15/2026 – Mirum Pharmaceuticals was given a new $146.00 price target by CLSA.
• 6/15/2026 – Mirum Pharmaceuticals had its price target raised by Citizens Jmp from $140.00 to $146.00. They now have a “market outperform” rating on the stock.
• 6/11/2026 – Mirum Pharmaceuticals had its price target raised by Morgan Stanley from $140.00 to $150.00. They now have an “overweight” rating on the stock.
• 6/8/2026 – Mirum Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 6/2/2026 – Mirum Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $145.00 price target on the stock.
• 6/1/2026 – Mirum Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/22/2026 – Mirum Pharmaceuticals was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 5/19/2026 – Mirum Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $145.00 price target on the stock.
• 5/19/2026 – Mirum Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $145.00 price target on the stock.
• 5/9/2026 – Mirum Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/7/2026 – Mirum Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 5/7/2026 – Mirum Pharmaceuticals had its price target raised by Royal Bank Of Canada from $128.00 to $142.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Mirum Pharmaceuticals had its price target raised by TD Cowen from $125.00 to $145.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Mirum Pharmaceuticals had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $165.00 price target on the stock.
• 5/7/2026 – Mirum Pharmaceuticals was given a new $185.00 price target by HC Wainwright.
• 5/7/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Evercore Inc. They now have a $138.00 price target on the stock.
• 5/7/2026 – Mirum Pharmaceuticals was given a new $136.00 price target by Stifel Nicolaus.
• 5/7/2026 – Mirum Pharmaceuticals was upgraded by Royal Bank Of Canada to “moderate buy”.
• 5/7/2026 – Mirum Pharmaceuticals had its price target raised by Robert W. Baird from $112.00 to $129.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Mirum Pharmaceuticals had its price target raised by Morgan Stanley from $130.00 to $140.00. They now have an “overweight” rating on the stock.
• 5/4/2026 – Mirum Pharmaceuticals had its price target raised by HC Wainwright from $150.00 to $175.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 5,000 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $93.82, for a total transaction of $469,100.00. Following the completion of the transaction, the chief financial officer owned 44,788 shares in the company, valued at approximately $4,202,010.16. This represents a 10.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the completion of the sale, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,594 shares of company stock valued at $3,608,758 over the last ninety days. 8.32% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.